BI-505, a human anti-ICAM-1 monoclonal antibody, was evaluated in multiple myeloma patients (NCT01025206), and it demonstrated good tolerability, along with efficacy in 7 of 29 patients who had stable disease for at least 8 weeks. Here, ICAM1 is linked to plasma cell myeloma.